Literature DB >> 22119973

The management of anxiety and knowledge of serum CA-125 after an ovarian cancer diagnosis.

Amanda Reid1, Elizabeth Ercolano, Peter Schwartz, Ruth McCorkle.   

Abstract

This article describes the relationship among anxiety, distress, and serum CA-125 levels in women with ovarian cancer. Women's anxiety about monitoring their CA-125 levels during chemotherapy also is discussed. Data from a randomized trial including self-reported anxiety and emotional distress of women following surgery after a primary diagnosis of ovarian cancer, their recorded serum CA-125 levels, and knowledge about their CA-125 levels were analyzed. In the sample, 26 of 30 women had serum CA-125 levels above the normal range. At baseline, the sample had an elevated mean anxiety score and an elevated distress score. A moderate association was found between a high serum CA-125 level and a high anxiety score at baseline, but the finding was not statistically significant. A negative nonsignificant relationship was found between a high serum CA-125 level and distress at baseline. The qualitative analysis revealed two themes: anxiety and lack of knowledge of serum CA-125. Oncology nurses and nurse practitioners caring for these women should provide essential information and strategies that can help guide women with ovarian cancer through the journey of their disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119973     DOI: 10.1188/11.CJON.625-632

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  5 in total

1.  Frequency of psychological distress in gynecologic cancer patients seen in a large urban medical center.

Authors:  Hannah F Cassedy; Christy Tucker; Linda S Hynan; Renee Phillips; Cassandra Adams; Marian R Zimmerman; Sandra Pitts; Paula Miltenberger; C Allen Stringer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-03-15

2.  Association of ß-hCG Surveillance with Emotional, Reproductive, and Sexual Health in Women Treated for Gestational Trophoblastic Neoplasia.

Authors:  Elizabeth L Jewell; Carol Aghajanian; Margaret Montovano; Sharyn N Lewin; Raymond E Baser; Jeanne Carter
Journal:  J Womens Health (Larchmt)       Date:  2017-12-21       Impact factor: 2.681

3.  Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer.

Authors:  Daniel Krell; Fran Said Battistino; Sarah Benafif; Lochani Ganegoda; Marcia Hall; Gordon J S Rustin
Journal:  Int J Gynecol Cancer       Date:  2017-07       Impact factor: 3.437

4.  Tumor marker response to SARS-CoV-2 infection among patients with cancer.

Authors:  Alexander H Gunn; Carolyn Tashie; Steven Wolf; Jesse D Troy; Yousuf Zafar
Journal:  Cancer Med       Date:  2022-03-15       Impact factor: 4.711

Review 5.  Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancer.

Authors:  Cara Stabile; Abigail Gunn; Yukio Sonoda; Jeanne Carter
Journal:  Transl Androl Urol       Date:  2015-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.